New Preeclampsia Treatment May Safely Extend Pregnancy

What Is Severe Early-Onset Preeclampsia and Why Is It So Dangerous?

Preeclampsia is a multisystem hypertensive disorder of pregnancy characterized by new-onset high blood pressure and signs of organ dysfunction, typically involving the kidneys, liver, or central nervous system. The severe early-onset form, which develops before 34 weeks of gestation, is the most dangerous variant and is associated with placental dysfunction, fetal growth restriction, eclampsia, and HELLP syndrome. According to the World Health Organization, hypertensive disorders of pregnancy contribute to a significant share of maternal deaths globally, with preeclampsia and eclampsia among the leading causes.

Currently, the only definitive treatment is delivery of the baby and placenta. When preeclampsia turns severe well before term, clinicians face a difficult balancing act: continuing the pregnancy risks maternal stroke, organ failure, or stillbirth, while delivering early exposes the newborn to the serious complications of extreme prematurity, including respiratory distress syndrome, intraventricular hemorrhage, and long-term neurodevelopmental impairment. Even a few additional days in the womb can meaningfully improve neonatal outcomes.

How Does the New Cedars-Sinai Treatment Work?

According to the Cedars-Sinai research team, the experimental approach focuses on the underlying biology of preeclampsia rather than simply treating its symptoms. Preeclampsia is thought to arise from abnormal placental development and the release of anti-angiogenic factors such as soluble fms-like tyrosine kinase-1 (sFlt-1) into the maternal circulation, which damage blood vessels and drive hypertension, proteinuria, and end-organ injury. Strategies that modulate these pathways have been a major focus of obstetric research over the past decade.

In the early-phase study, investigators reported that the treatment was well tolerated and appeared to safely extend pregnancy in women with severe early disease who would otherwise have faced imminent delivery. While the findings are preliminary and will require larger randomized trials before any therapy could be approved, experts say the work represents one of the most promising directions in a field where treatment options have changed little in decades. If confirmed, such a therapy could help reduce the rate of medically indicated preterm birth, a major contributor to neonatal intensive care admissions.

What Could This Mean for Future Maternal Care?

Obstetric medicine has long lagged behind other specialties in pharmaceutical innovation, in part because pregnant women have historically been excluded from drug trials. As a result, the standard of care for severe preeclampsia still relies on antihypertensives, magnesium sulfate for seizure prevention, and timely delivery. A disease-modifying therapy that addresses the placental origins of the condition would mark a significant shift in clinical practice and could be particularly transformative in low- and middle-income countries, where preeclampsia accounts for a disproportionate share of maternal and neonatal deaths.

Experts caution that translating early findings into routine care will take years. Larger randomized controlled trials must confirm both efficacy and long-term safety for mothers and infants, including neurodevelopmental follow-up of children exposed in utero. Regulatory agencies such as the U.S. Food and Drug Administration have signaled increased interest in maternal health therapeutics, and patient advocacy groups continue to push for greater investment in obstetric research. Until then, clinicians emphasize that early prenatal care, blood pressure monitoring, and low-dose aspirin in high-risk pregnancies remain the most important tools for prevention.